Under construction – not a live service
Sign in
Taking people in ItalyNo phase

Studies MYC gene changes in two aggressive types of B-cell lymphoma

Observes MYC gene changes and immune environment in adults with aggressive B-cell lymphoma.

Plain-language title generated from the registry record
Registry title: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

Key facts

Where
Alessandria, Ancona, Bari, Brescia, Candiolo, Castelfranco Veneto, Catania, Civitanova Marche, Florence, Milan, Padova, Sassuolo, Siena, Torino, Treviso, Tricase, Trieste, and Verona, ItalySee the 20 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 79 years old?

Source: NCT06588205, who can take part

Where in Italy

  • A.O.U. SS. Antonio e Biagio e C. Arrigo - S.C.D.U. EmatologiaAlessandria, ItalyTaking people
  • A.O.U. Ospedali Riuniti delle Marche - Clinica di EmatologiaAncona, ItalyTaking people
  • I.R.C.C.S. Istituto Tumori Giovanni Paolo II - U.O.C. EmatologiaBari, ItalyTaking people
  • ASST Spedali Civili - S.C. EmatologiaBrescia, ItalyTaking people
  • I.R.C.C.S. Istituto di Candiolo - FPOCandiolo, ItalyTaking people
  • I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. OncoematologiaCastelfranco Veneto, ItalyNot yet recruiting
  • ARNAS Garibaldi - U.O.C. EmatologiaCatania, ItalyTaking people
  • A.S.T. Macerata - U.O.S.D EmatologiaCivitanova Marche, ItalyTaking people
  • Azienda Ospedaliera Universitaria Careggi - Unità funzionale di EmatologiaFlorence, ItalyTaking people
  • ASST Grande Ospedale Metropolitano Niguarda - S.C. EmatologiaMilan, ItalyTaking people
  • Ospedale Maggiore Policlinico Fondazione IRCCS Ca' Granda - S.C. EmatologiaMilan, ItalyTaking people
  • A.O.U. di Padova - U.O.C. EmatologiaPadova, ItalyNot yet recruiting
  • I.R.C.C.S. Istituto Oncologico Veneto - U.O.C. Oncologia 1Padova, ItalyNot yet recruiting
  • AUSL Modena sede di Sassuolo - UOSD di Oncologia Area SudSassuolo, ItalyTaking people
  • U.O.C. Ematologia - A.O.U. SeneseSiena, ItalyNot yet recruiting
  • A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia UTorino, ItalyNot yet recruiting
  • ULSS 2 Ospedale Ca' Foncello - U.O.C. EmatologiaTreviso, ItalyTaking people
  • A.O. Cardinale "G. Panico" - U.O.C Ematologia e Trapianto Midollo OsseoTricase, ItalyTaking people
  • A.S.U. Giuliano Isontina - S.C. EmatologiaTrieste, ItalyTaking people
  • A.O.U.I. di Verona - EmatologiaVerona, ItalyNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Fondazione Italiana Linfomi - ETS
Trial code
NCT06588205
Record updated
29 December 2025
Original description
This is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell LymphomaRead full original descriptionShow less

Multicenter, Observational, Retrospective-prospective Study Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

This is a observational, retrospective and prospective study designed to assess the potential correlations between MYC alterations, lymphoma mutational landscape and functional immune contextures in Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma

Inclusion: Diagnosis of nodal and extranodal Diffuse Large B Cell Lymphoma, High Grade B Cell Lymphomas (including low-grade transformed lymphomas; double and triple hit; 11q aberration; not otherwise specified) after 1st January 2019; Presence of one MYC translocation or gain of copies (GCN: > 3 copies in more than 30% of the nuclei) or amplification evaluated by FISH; Availability of immunohistochemical analysis of CD10, Bcl6, MUM1, Bcl2, Myc, Ki67; Have received curative treatment (e.g. R-CHOP, R DA EPOCH, intensified "Burkitt like" chemotherapies) as first-line therapy; Histological material of adequate size and quality to perform histological review with any additional investigations (immunohistochemistry, FISH and other molecular analysis). A FFPE block must be provided for patient enrollment; Age between 18 and 79 years.

Exclusion: Have received palliative treatment; Primary lymphomas of the central nervous system, plasmablastic lymphoma, Burkitt's lymphoma, primary mediastinal B lymphoma.

ClinicalTrials.gov NCT06588205